| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
|
Cancer Res
|
2009
|
1.79
|
|
2
|
Lack of correlation between the histologic and magnetic resonance imaging results of optic nerve involvement in eyes primarily enucleated for retinoblastoma.
|
Ophthalmology
|
2009
|
1.54
|
|
3
|
Improving the histopathologic diagnosis of pediatric malignancies in a low-resource setting by combining focused training and telepathology strategies.
|
Pediatr Blood Cancer
|
2012
|
1.39
|
|
4
|
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
|
J Clin Oncol
|
2007
|
1.20
|
|
5
|
Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
|
J Clin Oncol
|
2004
|
1.05
|
|
6
|
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
|
Pediatr Blood Cancer
|
2010
|
1.05
|
|
7
|
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
|
Pediatr Blood Cancer
|
2011
|
1.04
|
|
8
|
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
|
Pediatr Blood Cancer
|
2010
|
1.03
|
|
9
|
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
|
Pediatr Blood Cancer
|
2010
|
1.00
|
|
10
|
A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma.
|
Br J Ophthalmol
|
2010
|
0.96
|
|
11
|
Second cancers in patients with the Ewing sarcoma family of tumours.
|
Eur J Cancer
|
2008
|
0.96
|
|
12
|
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
|
Pediatr Blood Cancer
|
2008
|
0.95
|
|
13
|
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
|
J Clin Oncol
|
2006
|
0.94
|
|
14
|
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
|
Cancer Res
|
2009
|
0.88
|
|
15
|
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
|
Pediatr Blood Cancer
|
2012
|
0.86
|
|
16
|
Comparison of two methods for carboplatin dosing in children with retinoblastoma.
|
Pediatr Blood Cancer
|
2010
|
0.85
|
|
17
|
The role of PET/CT in assessing pulmonary nodules in children with solid malignancies.
|
AJR Am J Roentgenol
|
2013
|
0.82
|
|
18
|
Lymphocyte-predominant Hodgkin disease in children.
|
J Pediatr Hematol Oncol
|
2002
|
0.81
|
|
19
|
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
|
Clin Cancer Res
|
2002
|
0.81
|
|
20
|
Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
|
Clin Cancer Res
|
2002
|
0.80
|
|
21
|
Initial testing of aplidin by the pediatric pre-clinical testing program.
|
Pediatr Blood Cancer
|
2009
|
0.80
|
|
22
|
Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
|
Clin Cancer Res
|
2013
|
0.78
|
|
23
|
Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
0.77
|
|
24
|
Evaluation of pediatric oncology patients with previous multiple central catheters for vascular access: is Doppler ultrasound needed?
|
Pediatr Blood Cancer
|
2007
|
0.77
|
|
25
|
Incidence of anemia in children with solid tumors or Hodgkin disease.
|
J Pediatr Hematol Oncol
|
2002
|
0.77
|
|
26
|
Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions.
|
Childs Nerv Syst
|
2015
|
0.77
|
|
27
|
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
|
Cancer Chemother Pharmacol
|
2004
|
0.76
|